December 13, 2016
Eli Lilly cuts insulin prices
Eli Lilly has announced that people who use Lilly insulin will be able to access discounted prices for their purchases…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Eli Lilly
December 13, 2016
Eli Lilly announces dividend increase
The board of directors of Eli Lilly has announced a 2 percent increase in its quarterly dividend. The dividend for…
December 13, 2016
Type 2 diabetes gets new treatment in U.S., FDA OKs Boehringer’s Synjardy XR
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Synjardy XR tablets for adults with type 2 diabetes.…
December 12, 2016
Eli Lilly and AstraZeneca join forces to fight Alzheimer’s disease
Eli Lilly and AstraZeneca have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which…
December 9, 2016
Alzheimer’s disease drug study disappoints Lilly
Eli Lilly has presented detailed results of its disappointing phase 3 Expedition3 trial at the 9th Clinical Trials on Alzheimer’s…
November 8, 2016
BD launches first syringe designed for use with Humulin R U-500 insulin
BD has announced the launch of the BD U-500 Insulin Syringe, the first insulin syringe developed for people with diabetes taking Humulin …
November 4, 2016
Drugmakers under fire for possible U.S. price fixing
Two prominent U.S. lawmakers on Thursday called on federal antitrust regulators to probe whether Sanofi SA, Eli Lilly and Co, Merck…
November 2, 2016
Eli Lilly, Incyte’s rheumatoid arthritis drug studies show positive effect
Eli Lilly and Company and Incyte Corporation have announced on Wednesday that new data from RA-BEACON – a pivotal phase 3 study…
October 27, 2016
Newly approved drugs push Lilly’s revenues 5% up, but net income went 3% down
The world’s leading drugmaker Eli Lilly saw a decline in net income for the third…
October 20, 2016
FDA approves Lilly’s Lartruv for soft tissue sarcoma treatment
Eli Lilly and Company announced that FDA has granted approval of LARTRUV (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the treatment of adults with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.